Skip to main content
Premium Trial:

Request an Annual Quote

LexaGene Closes C$6.6M Financing Round

NEW YORK – LexaGene said today that it has closed a previously announced financing round, grossing C$6.7 million (US$5.1 million).

The Beverly, Massachusetts-based firm, which trades on the Toronto Stock Exchange, will use the net proceeds for research and development, marketing, and general corporate purposes to support commercialization efforts of its LX Analyzer technology, which uses microfluidic PCR for pathogen detection. 

LexaGene said it sold 12,769,626 units at an offering of C$.52 per unit. Each unit consisted of one common share and one common share purchase warrant, entitling the holder to acquire a share at a price of C$.75 per common share until Oct. 29, 2022. 

The financing round was conducted by Industrial Alliance Securities, which LexaGene issued an aggregate of 735,229 broker warrants. Each broker warrant entitles the holder to purchase one share at the price of C$.52 per share until Oct. 29, 2022.

"We would like to thank our current shareholders for their continued support, and we welcome our new retail and institutional shareholders to LexaGene with this raise," LexaGene CEO Jack Regan said in a statement. 

LexaGene previously completed a C$2.8M private placement in March. 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more